



# Errata

**Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249**

<https://doi.org/10.2337/dc17-er06>

The supplementary data originally attached to the article cited above was incorrect. The correct version of the supplementary data has been attached to the online version of the article.

*Christof M. Kazda, Ying Ding,  
Ronan P. Kelly, Parag Garhyan,  
Chunxue Shi, Chay Ngee Lim, Haoda Fu,  
David E. Watson, Andrew J. Lewin,  
William H. Landschulz, Mark A. Deeg,  
David E. Moller, and Thomas A. Hardy*